Plain language summary of zanubrutinib or ibrutinib in chronic
lymphocytic leukemia that is resistant to treatment or has come
back after treatment

j 2024

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment

BROWN, Jennifer R; Barbara EICHHORST; Peter HILLMEN; Wojciech JURCZAK; Maciej KAZMIERCZAK et. al.

Basic information

Original name

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment

Authors

Edition

Future Oncology, London, Future Medicine Ltd. 2024, 1479-6694

Other information

Language

English

Type of outcome

Article in a journal (not reviewed)

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 3.000 in 2023

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2217/fon-2023-0849

UT WoS

001125061500001

Keywords in English

Hematologic/Leukemia; ibrutinib; plain language summary; treatment resistance; zanubrutinib

Abstract

V originále

What is this summary about?This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at least once for, relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Lymphocytes help to find and fight off viruses and infections in the body, but when someone has CLL or SLL, the body creates abnormal lymphocytes, leaving the patient with a weakened immune system and susceptible to illness. In CLL, these lymphocytes are in the bone marrow and bloodstream, whereas for SLL, they are mostly found in the lymph nodes, such as those in the neck.How was the research done?The ALPINE study was designed to directly compare the cancer-fighting effects and side effects of zanubrutinib and ibrutinib as treatment for patients with relapsed or refractory CLL/SLL.What were the results?After 30 months, zanubrutinib was more effective than ibrutinib at reducing and keeping the cancer from coming back.

Cite

BROWN, Jennifer R; Barbara EICHHORST; Peter HILLMEN; Wojciech JURCZAK; Maciej KAZMIERCZAK; Nicole LAMANNA; Susan M O'BRIEN; Constantine S TAM; Lugui QIU; Keshu ZHOU; Martin SIMKOVIC; Jiří MAYER; Amanda GILLESPIE-TWARDY; Alessandra FERRAJOLI; Peter S GANLY; Robert WEINKOVE; Sebastian GROSICKI; Andrzej MITAL; Tadeusz ROBAK; Anders OSTERBORG; Habte A YIMER; Tommi SALMI; Megan-Der-Yu WANG; Lina FU; Jessica LI; Kenneth WU; Aileen COHEN and Mazyar SHADMAN. Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncology. London: Future Medicine Ltd., 2024, vol. 20, No 12, p. 717-726. ISSN 1479-6694. Available from: https://dx.doi.org/10.2217/fon-2023-0849.

@article{2423208,
   author = {Brown, Jennifer R and Eichhorst, Barbara and Hillmen, Peter and Jurczak, Wojciech and Kazmierczak, Maciej and Lamanna, Nicole and O'Brien, Susan M and Tam, Constantine S and Qiu, Lugui and Zhou, Keshu and Simkovic, Martin and Mayer, Jiří and GillespieandTwardy, Amanda and Ferrajoli, Alessandra and Ganly, Peter S and Weinkove, Robert and Grosicki, Sebastian and Mital, Andrzej and Robak, Tadeusz and Osterborg, Anders and Yimer, Habte A and Salmi, Tommi and Wang, MeganandDerandYu and Fu, Lina and Li, Jessica and Wu, Kenneth and Cohen, Aileen and Shadman, Mazyar},
   article_location = {London},
   article_number = {12},
   doi = {http://dx.doi.org/10.2217/fon-2023-0849},
   keywords = {Hematologic/Leukemia; ibrutinib; plain language summary; treatment resistance; zanubrutinib},
   language = {eng},
   issn = {1479-6694},
   journal = {Future Oncology},
   title = {Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment},
   url = {https://www.tandfonline.com/doi/full/10.2217/fon-2023-0849},
   volume = {20},
   year = {2024}
}

TY  - JFULL
ID  - 2423208
AU  - Brown, Jennifer R - Eichhorst, Barbara - Hillmen, Peter - Jurczak, Wojciech - Kazmierczak, Maciej - Lamanna, Nicole - O'Brien, Susan M - Tam, Constantine S - Qiu, Lugui - Zhou, Keshu - Simkovic, Martin - Mayer, Jiří - Gillespie-Twardy, Amanda - Ferrajoli, Alessandra - Ganly, Peter S - Weinkove, Robert - Grosicki, Sebastian - Mital, Andrzej - Robak, Tadeusz - Osterborg, Anders - Yimer, Habte A - Salmi, Tommi - Wang, Megan-Der-Yu - Fu, Lina - Li, Jessica - Wu, Kenneth - Cohen, Aileen - Shadman, Mazyar
PY  - 2024
TI  - Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment
JF  - Future Oncology
VL  - 20
IS  - 12
SP  - 717-726
EP  - 717-726
PB  - Future Medicine Ltd.
SN  - 14796694
KW  - Hematologic/Leukemia
KW  - ibrutinib
KW  - plain language summary
KW  - treatment resistance
KW  - zanubrutinib
UR  - https://www.tandfonline.com/doi/full/10.2217/fon-2023-0849
N2  - What is this summary about?This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at least once for, relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Lymphocytes help to find and fight off viruses and infections in the body, but when someone has CLL or SLL, the body creates abnormal lymphocytes, leaving the patient with a weakened immune system and susceptible to illness. In CLL, these lymphocytes are in the bone marrow and bloodstream, whereas for SLL, they are mostly found in the lymph nodes, such as those in the neck.How was the research done?The ALPINE study was designed to directly compare the cancer-fighting effects and side effects of zanubrutinib and ibrutinib as treatment for patients with relapsed or refractory CLL/SLL.What were the results?After 30 months, zanubrutinib was more effective than ibrutinib at reducing and keeping the cancer from coming back.
ER  -

BROWN, Jennifer R; Barbara EICHHORST; Peter HILLMEN; Wojciech JURCZAK; Maciej KAZMIERCZAK; Nicole LAMANNA; Susan M O'BRIEN; Constantine S TAM; Lugui QIU; Keshu ZHOU; Martin SIMKOVIC; Jiří MAYER; Amanda GILLESPIE-TWARDY; Alessandra FERRAJOLI; Peter S GANLY; Robert WEINKOVE; Sebastian GROSICKI; Andrzej MITAL; Tadeusz ROBAK; Anders OSTERBORG; Habte A YIMER; Tommi SALMI; Megan-Der-Yu WANG; Lina FU; Jessica LI; Kenneth WU; Aileen COHEN and Mazyar SHADMAN. Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. \textit{Future Oncology}. London: Future Medicine Ltd., 2024, vol.~20, No~12, p.~717-726. ISSN~1479-6694. Available from: https://dx.doi.org/10.2217/fon-2023-0849.

Přehled o publikaci